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The vasopressin gene is highly transcribed in magnocellular neurons of the supraoptic (SON) and paraventricular nucleus (PVN) in the rat hypotha- 
lamus. In order to identify c&acting elements involved in the expression of the vasopressin gene, approximately 1 kb upstream of the transcription 
start site has been sequenced. Several putative regulatory elements have been detected, including a glucocorticoid response lement (GRE), a CAMP 
response element (CRE), and four AP2 binding sites. In gel shift assays performed with a labelled DNA fragment corresponding to nucleotide 
residues -214 to -36 and nuclear proteins extracted from SON-derived tissue enriched in magnocellular neurons, three specific protein-DNA com- 
plexes have been detected. Complex formation is effectively competed by addition of an excess of unlabelled fragment. 
Vasopressin gene expression; Glucocorticoid response lement; Binding site, AP2; cyclic AMP response lement; Gel shift assay; Nuclear protein 
fraction 
1. INTRODUCTION 
To date little is known about the molecular events 
governing the expression of the gene encoding the pre- 
cursor for the peptide hormone vasopressin. In the rat 
and human genome, the vasopressin gene is linked to 
the closely related oxytocin gene [1,2]. Yet the two 
genes are transcribed in different subtypes of magno- 
cellular neurons of the supraoptic (SON) and paraven- 
tricular nucleus (PVN) of the hypothalamus [3]. Al- 
though both hormones control rather different physio- 
logical functions in the organism, e.g. water retention 
in the kidney (vasopressin) and smooth muscle contrac- 
tion in the uterus (oxytocin), there are several reports 
that demonstrate a concomitant upregulation in the ex- 
pression of the vasopressin and oxytocin genes under 
various physiological conditions. For instance prolong- 
ed osmotic stimulation of rats results not only in a 
2-3-fold increase of vasopressin message [4], but also of 
oxytocin-encoding mRNA in magnocellular neurons 
[5]. A similar rise in vasopressin- and oxytocin- 
encoding transcripts has also been shown to occur dur- 
ing late gestation and lactation [6]. On the other hand, 
after systemic administration of vasopressin, a reduc- 
tion in the two mRNA species has been observed in rat 
hypothalami [7]. 
segment upstream of the transcriptional start site of the 
vasopressin gene has been sequenced and analyzed for 
regulatory elements. 
2. MATERIALS AND METHODS 
2. I. Sequence analysis and preparation of nuclear extracts 
Nucleotide sequence was determined as reported [3]. Where speci- 
fied male Wistar rats were treated with 2% saline for seven days. SON 
were dissected from about 1.5 mm thick brain slices and collected in 
ice-cold PBS (150 mM NaCl, 10 mM sodium phosphate, pH 7.2). 
Tissue pools from 5 animals were frozen in liquid nitrogen after re- 
moval of PBS. Nuclei from SON tissue or from cerebellum were pre- 
pared as published [8]. Nuclear proteins were extracted [9] and their 
protein concentration determined [lo]. Aliquots of nuclear protein 
were frozen in liquid nitrogen and stored at - 80°C. 
2.2. Mobility shift assay 
To gain an initial insight into the mechanisms con- 
trolling the expression of the vasopressin gene, a DNA 
Binding reactions contained 3.5 yg nuclear protein, 3 fig poly 
(dJdC), 20 ng sonicated E. coli DNA in 10 mM Hepes, pH 7.9, 10% 
glycerol, 50 mM KCl, 0.25 mM PMSF, 5 mM DTT, 1 mM EDTA. 
Prior to the addition of labelled DNA fragment (2.5 fmol/reaction), 
binding reactions were preincubated for 15 min at 4°C. Labelled 
DNA and if included, unlabelled competitor DNAs (see legend to 
fig.3) were added simultaneously. The mixture was incubated at 4°C 
for 30 min and immediately loaded on 4% prerun acrylamide gels 
(acrylamide: bisacrylamide 80: 1). Electrophoresis was performed for 
2 h (20 mA) at room temperature in 6.7 mM Tris-HCl, pH 7.5, 
3.3 mM sodium acetate, 1 mM EDTA, with constant buffer circula- 
tion. Gels were dried and exposed to X-ray film at -80°C for 
15-24 h. 
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2.3. Labeliing of DNA fragments 
The nucleotide sequence(s) presented here has (have) been submitted 
to the EMBL/GenBank database under the accession number no. 
YO531 
377 bp (- 751 to - 374) and 338 bp (- 374 to - 36) PstI DNA frag- 
ments derived from the 5’ region of the rat vasopressin gene were sub- 
cloned individually into the PstI site of pUC9. DNA fragments were 
labelled at the unique SalI- or HindHI-site of the vector by filling in 
the 5’ cohesive ends with [cY-“P]dCTP (sp. act. 3000 Ci/mmol) and 
Klenow polymerase according to standard procedures [ll]. Subse- 
quently, DNAs were recut with AhaII (- 561) and Bali (- 214) re- 
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spectively. The fragments were electrophoretically eluted from native 
8010 polyacrylamide gels [12]. The specific activity of the labelled frag- 
ments ranged between 4 and 8 x 10’ cpm/pg. 
3. RESULTS AND DISCUSSION 
The rat vasopressin gene was previously subcloned as 
a 3.2 kb DNA fragment (pRAVP 3.2) excised from a 
18 kb genomic clone harbouring both the vasopressin 
and oxytocin gene [l]. In addition to the complete cod- 
ing region, clone pRAVP 3.2 contains roughly 1 kb of 
5 ’ untranscribed DNA (fig. 1A). Several putative cis- 
acting elements located proximal and distal to the tran- 
scriptional start site were identified on the basis of their 
homology with known truns-acting factor binding sites 
(table 1). 
At position - 247 a CCAAT motif is found, the pres- 
ence of such an element being known to increase the 
constitutive rate of transcription in many genes [13]. 
Further downstream at position - 227, a region resem- 
bling a CAMP response element (CRE) is present. The 
putative CRE differs from the classical octamer se- 
quence 5 ’ TGACGTCA 3 ’ in 2 positions yielding a non- 
palindromic sequence. Nevertheless, it is well docu- 
mented that CRE-like sequences found in promoter re- 
gions of other genes show deviations from the classical 
sequence but are still CAMP-responsive [ 141. 
Four elements, fitting the consensus sequence for 
transcription factor AP2 binding sites [15] were found 
at position - 345, - 146, - 95, and - 84. AP2 has been 
shown to bind to the SV40 enhancer as well as to the 
promoter regions of various cellular genes, and to stim- 
ulate the rate of transcription by protein kinase A and 
C dependent pathways [15]. A sequence similar to a 
glucocorticoid response element (GRE) is present more 
distally at nucleotide position -622. Detailed analysis 
of functional GREs present in several genes has led to 
the conclusion that the last six nucleotide residues 5TG- 
TYCT 3 ’ within the GRE motif are strongly conserved, 
while there is a greater degree of variability intrinsic in 
the nucleotides at the 5 ’ end of the element [16]. 
In order to identify nuclear proteins that bind to the 
putative promoter regions of the AVP gene protein- 
DNA binding experiments were performed using four 
different DNA fragments (schematically outlined in 
fig. 1B) and nuclear extracts prepared either from SON 
tissue or from cerebellum of rats treated with 2% saline. 
In vitro, three complexes I, II, and III are formed when 
a SON-derived nuclear protein fraction was added to 
the most proximal promoter fragment 1 (position - 214 
to - 36), which harbours three putative AP2 binding 
sites (fig.2, lane 2), but none of the other c&acting ele- 
ments mentioned above. No complex formation was 
observed with DNA fragments 2-4 (fig.2, lanes 4,6,8) 
although at least DNA fragment 2 contains, in addition 
to one putative AP2 binding site, a CCAAT motif and 
a CRE-like sequence. The failure to detect a pro- 
tein/DNA complex could be due to the low amount of 
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Table 1 
Putative regulatory elements in the 5 ’ region of the rat vasopressin 
gene 
CRE 
consensus 
- 221 
5’ 3’ 
TGACGTCA 
TCCCGTCA - 220 
AP2 binding site 5’ 3’ 
consensus TCCCCAK N G/C C/G G/C 
- 336 TCCCC A G G T C -345 
-146 TCCCC A G A T G - 137 
- 86 TCCCC A G G A G - 95 
- 75 TCCCC A G T G G - 84 
GRE 5’ 3’ 
consensus GGTACANNNTGTYCT 
- 622 TGTCACAACTGTCCT - 608 
AP2, activator protein 2; CRE, CAMP response element; GRE, 
glucocorticoid response element. The numbering indicates the posi- 
tion of the elements upstream of the transcriptional start site (1). The 
bold letters are in agreement with published sequence motifs 
protein used in these experiments. Unfortunately, the 
small number of vasopressinergic neurons per rat brain 
(about 5000 cells [ 171) precludes the preparation of nu- 
clear protein in higher amounts. The AP2-like elements 
may, on the other hand, represent low affinity binding 
sites so that stable complexes cannot be formed under 
the experimental conditions used. Alternatively, respec- 
tive proteins may act to modulate the transcriptional 
rate of the vasopressin gene only during certain devel- 
opmental stages, physiological conditions, or in non- 
neuronal tissues. 
To decide whether complexes I to III result from in- 
teractions between DNA fragment 1 and proteins re- 
stricted to magnocellular neurons, mobility shift experi- 
ments similar to those described above were carried out 
with a nuclear protein fraction extracted from rat cere- 
bellum tissue. One complex exhibiting an electro- 
phoretic mobility very similar or identical to complex I 
was formed upon incubation with DNA fragment 1 
(fig.2, lane 1); however once again no shifted bands 
were present after addition of fragments 2,3 or 4 to the 
binding reactions (fig.2, lanes 3,5,7). The binding of 
nuclear proteins from SON, as well as from cerebellum, 
to DNA fragment 1 seems to be specific, because an ex- 
cess of unlabelled fragment 1 effectively competed for 
binding to the labelled DNA (fig.3, lanes 2,6). In con- 
trast, the same molar excess of unlabelled fragment 2, 
or of a 183 bp DNA fragment excised from pUC9 by re- 
striction enzymes PvuII and HindIII, was not able to 
inhibit complex formation (fig.3, lanes 3,4,7,8). None 
of these complexes appears to arise from interaction of 
APZlike proteins with DNA fragment 1. Addition of 
synthetic double-stranded oligonucleotides (30-mers) 
centrally harbouring the individual putative AP2 bind- 
ing sites as competitors, did not abolish the formation 
of complexes I, II, or III respectively (data not shown). 
This finding is in agreement with a failure of unlabelled 
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TOCCCCACCTCCTGGTCCTGACCCTGCTGCAGACCTGCTAGTCCTTGGTGAATGAGACCTGGGGACCCCTCTAGTCTG~GAGAGCTGCTG~TGCTCA 
ACGOOCTGGAGGACCACGACTGGGACGACGTCTGGACGATCAGGAACCACTTACT GGGAGATCAGACMCTCTCGACGACTTTACGAGT 
ACTA~A~CCAGGTCACCCTCAAGTCGGCTCACCTCCCTGATTGCACAGCA~ACTGTGGC~T~C~CACGGTGGCCAG~ACAGC 
n;ATACTAMGGTCCACTGGGAGTTCAGCCGAGTGG~GGGACTAACGTGTCGTGG~AGTGACACCGCCACCGAG~CAGTGTGCCACCGGTCACTGTCG 
ClYiATCGCTCGCTCCCCTCCTCCACCACCCTCTGCATTGACAGGCCCACGTGT CTGMTCACTGCTGACAGCTTGGGACCTGTCAGCT 
GACTACCGACCGAGGGGAGGAGGTGGTGGGAGACGTAACTGTCCGGGTGCACACAGGGGTCTACGGACTTAGTGACGACTGTCGAACCCTGGACAGTCGA 
GTOCGCTCCTGGGGAGCCACTGGGGAGGGGGTTAGCAGCCACGCTGTCGCCTCCTAGCCAACACCTGCAG A ACAGCCCAGCCCGCTCAGGC 
CACCCG GGACCCCTC 
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Fig.1. (A) Nucleotide sequence of the 5’ region of the rat vasopressin gene. The modified TATA box is underlined. Putative binding sites foI 
glucocorticoid receptor (GR), CCAAT-box binding proteins, CAMP response lement binding protein (CREB) and AP2 are indicated by arrows. 
The protein coding regions and the intron sequences of the vasopressin gene are not shown. The asterisk marks the transcriptional start point. (B) 
Schematic representation of the rat vasopressin gene, the deduced hormone precursor structure and the derived DNA fragments (fl to f4) used 
in mobility shift assays. The numbers indicate the position relative to the transcriptional start point (+ 1). S, signal peptide; V, vasopressin; N, 
neurophysin; G, glycopeptide; A, B, C, indicate the three: exons of the vasopressin gene, I and II, the two introns. 
1 2345678 
12 34 56 78 
Fig.2. Mobility shift assay. Nuclear protein fraction extracted from 
rat cerebellum (lanes 1,3,5,7) or SON tissue (lanes 2,4,6,8) was in- 
cubated with 2.5 fmol each of “P-1abelled DNA derived from the 5 ’ 
region of the rat vasopressin gene. Lanes 1,2: fragment 1 (- 214 to 
- 36); lanes 3,4: fragment 2 (- 374 to -214); lanes 5,6: fragment 3 
(- 561 to - 374); lanes 7,8: fragment 4 (- 751 to - 561). F, unbound 
probe; I, II, 111, bound probe. 
Fig.3. Mobility shift assay. Nuclear protein fraction extracted from 
rat SON tissue (lanes l-4) or cerebellum (lanes (5-8) was incubated 
with 2.5 fmol of “P-1abelled DNA fragment 1 (- 214 to - 36) in the 
absence (lanes 1.5) or presence of various unlabelled competitor 
DNAs, added in a -30-fold molar excess. Lanes 2,6: unlabelled frag- 
ment 1; lanes 3,7: unlabelled fragment 2; lanes 4,8: unlabelled pIJC9 
DNA. F, unbound probe; I, II, III, bound probe. 
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DNA fragment 2 to inhibit or reduce the formation of 
any complex in the competition experiments described 
above, as well as the lack of complex formation be- 
tween DNA fragment 2 and SON nuclear protein. The 
data may indicate that at least complexes II and III 
represent cell type-specific protein factor(s) bound to 
presently unknown enhanaer and/or promoter elements 
within DNA fragment 1. Complex I, on the other hand, 
seems to contain a protein, which is not restricted to 
magnocellular neurons, and which might therefore 
function as a more general transcription factor. 
The gel shift data suggest he existence of proteins in 
magnocellular neurons of the SON that can specifically 
bind to a DNA fragment, which spans the 5’ region 
from nucleotide -214 to -36. One of the putative 
trans-acting factors is probably also present in cerebel- 
lum nuclei, thus representing a more ubiquitous pro- 
tein. A precise characterization of protein-DNA con- 
tact sites by footprint analysis is rendered technically 
extremely difficult due to the small number of vasopres- 
sinergic neurons present in the hypothalamus (approx- 
imately 5000 cells per rat brain [17]). Thus linkage of 
the putative &-acting elements of the promoter region 
of the AVP gene to a heterologous promoter should 
help to clarify whether these elements would be respon- 
sive to externally added stimuli. 
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